Shaw Megan L
Department of Microbiology, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, New York, New York 10029, United States.
ACS Infect Dis. 2017 Oct 13;3(10):691-694. doi: 10.1021/acsinfecdis.7b00142. Epub 2017 Sep 11.
Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients.
目前，流感治疗的选择仅限于一类药物，即神经氨酸酶抑制剂。在对耐药性的担忧中，人们付出了巨大努力来发现具有不同靶点和作用机制的新药，并取得了巨大成功。现在有几种处于后期开发阶段的候选药物，包括针对病毒聚合酶复合体三个亚基的小分子药物、针对血凝素的单克隆抗体，以及针对宿主的疗法。现在有了具有多种作用机制的药物，这为探索流感联合疗法打开了大门，而且给药途径的范围为治疗住院患者提供了更多机会。
